Shanghai Pharmaceutical (601607.SH) announced that recently, the company and HUYABIO reached an exclusive licensing agreement to license SPH6162 with independent intellectual property rights to HUYABIO, SPH6162 with independent intellectual property rights for a transaction amount of not more than US$292.5 million (in addition to sales commissions) outside the China region (including Hong Kong, China, Macau and Taiwan, the same below). The relevant rights and interests in the China region remained owned by Shanghai Pharmaceutical.
According to the announcement, SPH6162 is an anti-tumor small molecule inhibitor independently developed by shanghai Pharmaceutical Academia Sinica, which inhibits the damage repair of tumor cells to drugs by inhibiting kinase activity, so as to achieve tumor cell killing.
It is reported that the overseas authorization of SPH6162 further confirms the company's research and development strength, which is conducive to improving the company's international influence. SPH6162 is a fast-track product for global target development, with the help of overseas partners' resources and R&D strength, it is expected to accelerate the synchronous development of this product at home and abroad. Through cooperation with overseas pharmaceutical companies, we will further explore the development and listing path of overseas clinical trials, laying the foundation for the company's subsequent innovative products to go overseas.
This article originated from Zhitong Finance Network
![Where to apply for the "ICP License", and the conditions and procedures for handling it are explained in detail[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)